Prelude Therapeutics reports third quarter net loss of $19.7 million

Reuters

2025/11/12

Prelude <a href="https://laohu8.com/S/LENZ">Therapeutics</a> reports third quarter net loss of $19.7 million

Prelude Therapeutics Inc. reported a net loss of $19.7 million, or $0.26 per share, for the three months ended September 30, 2025, compared to $32.3 million, or $0.43 per share, for the same period in 2024. Non-cash expenses related to share-based payments were $2.4 million, down from $5.9 million in the prior year period. As of September 30, 2025, cash, cash equivalents, restricted cash and marketable securities totaled $58.2 million. The company subsequently received an additional license payment from AbCellera in October 2025 and $60.0 million from Incyte in November 2025. Prelude anticipates that its current funds will support operations into 2027. The company also presented new preclinical data at the European Hematology Association 2025 Congress and will present updated data at the American Society of Hematology Annual Meeting in December 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prelude Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9573804-en) on November 12, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2582375834"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582375834\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582375834?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582375834","market":"nz","top_or_hot":-1,"title":"Prelude Therapeutics reports third quarter net loss of $19.7 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Prelude <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> reports third quarter net loss of $19.7 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PRLD\">Prelude Therapeutics Inc</a>. reported a net loss of $19.7 million, or $0.26 per share, for the three months ended September 30, 2025, compared to $32.3 million, or $0.43 per share, for the same period in 2024. Non-cash expenses related to share-based payments were $2.4 million, down from $5.9 million in the prior year period. As of September 30, 2025, cash, cash equivalents, restricted cash and marketable securities totaled $58.2 million. The company subsequently received an additional license payment from AbCellera in October 2025 and $60.0 million from Incyte in November 2025. Prelude anticipates that its current funds will support operations into 2027. The company also presented new preclinical data at the European Hematology Association 2025 Congress and will present updated data at the American Society of Hematology Annual Meeting in December 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prelude Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9573804-en) on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Prelude Therapeutics reports third quarter net loss of $19.7 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPrelude Therapeutics reports third quarter net loss of $19.7 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-12 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Prelude <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> reports third quarter net loss of $19.7 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PRLD\">Prelude Therapeutics Inc</a>. reported a net loss of $19.7 million, or $0.26 per share, for the three months ended September 30, 2025, compared to $32.3 million, or $0.43 per share, for the same period in 2024. Non-cash expenses related to share-based payments were $2.4 million, down from $5.9 million in the prior year period. As of September 30, 2025, cash, cash equivalents, restricted cash and marketable securities totaled $58.2 million. The company subsequently received an additional license payment from AbCellera in October 2025 and $60.0 million from Incyte in November 2025. Prelude anticipates that its current funds will support operations into 2027. The company also presented new preclinical data at the European Hematology Association 2025 Congress and will present updated data at the American Society of Hematology Annual Meeting in December 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prelude Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9573804-en) on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4505","symbol_name":"高瓴资本持仓","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL81FsCh:1","article_id":"2582375834","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582375834","pubTimestamp":1762948936,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Prelude Therapeutics Inc. reported a net loss of $19.7 million, or $0.26 per share, for the three months ended September 30, 2025, compared to $32.3 million, or $0.43 per share, for the same period in 2024. Non-cash expenses related to share-based payments were $2.4 million, down from $5.9 million in the prior year period. As of September 30, 2025, cash, cash equivalents, restricted cash and marketable securities totaled $58.2 million. The company subsequently received an additional license payment from AbCellera in October 2025 and $60.0 million from Incyte in November 2025. Prelude anticipates that its current funds will support operations into 2027. The company also presented new preclinical data at the European Hematology Association 2025 Congress and will present updated data at the American Society of Hematology Annual Meeting in December 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4505":"高瓴资本持仓","BK4535":"淡马锡持仓","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","PRLD":"Prelude Therapeutics Inc","INCY":"因塞特医疗","BK4588":"碎股","BK4550":"红杉资本持仓","ABCL":"AbCellera Biologics","BK4112":"金融交易所和数据","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4532":"文艺复兴科技持仓","BK4121":"生命科学工具和服务","BK4585":"ETF&股票定投概念","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4139":"生物科技"},"translate_title":"Prelude Therapeutics报告第三季度净亏损1970万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABCL":0.9,"PRLD":0.9,"INCY":0.9,"NDAQ":0.9},"content_text":"Prelude Therapeutics reports third quarter net loss of $19.7 million\n    \n\nPrelude Therapeutics Inc. reported a net loss of $19.7 million, or $0.26 per share, for the three months ended September 30, 2025, compared to $32.3 million, or $0.43 per share, for the same period in 2024. Non-cash expenses related to share-based payments were $2.4 million, down from $5.9 million in the prior year period. As of September 30, 2025, cash, cash equivalents, restricted cash and marketable securities totaled $58.2 million. The company subsequently received an additional license payment from AbCellera in October 2025 and $60.0 million from Incyte in November 2025. Prelude anticipates that its current funds will support operations into 2027. The company also presented new preclinical data at the European Hematology Association 2025 Congress and will present updated data at the American Society of Hematology Annual Meeting in December 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prelude Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9573804-en) on November 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}